A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
Open Access
- 7 June 2011
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (1), 53-57
- https://doi.org/10.1038/bjc.2011.206
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Phase I/II Study of FOLFIRI in Japanese Patients with Advanced Colorectal CancerJapanese Journal of Clinical Oncology, 2010
- Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphismCancer Science, 2010
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Insights, Challenges, and Future Directions in IrinogeneticsTherapeutic Drug Monitoring, 2007
- Management of advanced colorectal cancer: state of the artBritish Journal of Cancer, 2006
- The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2006
- Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986Journal of Clinical Oncology, 2005
- Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced ToxicityClinical Cancer Research, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004